Hospital da Senhora da Oliveira, Guimarães, Portugal.
Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal.
Rev Neurol. 2022 Oct 1;75(7):189-197. doi: 10.33588/rn.7507.2022123.
Neurodevelopmental disorders have a multifactorial etiology that results from the interaction between biological and environmental factors. The biological basis of many of these disorders is only partially understood, which makes therapeutic interventions, especially pharmacological ones, particularly difficult. The impact of medical cannabis on neurological and psychiatric disorders has been studied for a long time. This study aimed to review the currently available clinical and pre-clinical studies regarding the use of cannabinoids in pediatric neurodevelopmental disorders and to draw attention to the potential therapeutic role of cannabidiol in this field.
Cannabidiol is an endocannabinoid system modulator and exerts its effects on both developing and mature brains through numerous mechanisms. Cannabidiol holds a relatively high toxicity limit and current literature suggests that it may have anxiolytic, antipsychotic, and neuroprotective properties. Clinical evidence suggests that early treatment with cannabidiol might be a promising therapy for neurodevelopmental disorders, including intellectual disability, autism spectrum disorders, tics, and attention/deficit hyperactivity disorder.
This review hopefully draws attention to an emerging body of evidence concerning cannabidiol's significant potential to safely improve many of the common symptoms affecting children and adolescents with neurodevelopmental disorders, especially autism spectrum disorder.
神经发育障碍的病因具有多因素性,是生物因素和环境因素相互作用的结果。这些疾病的许多生物学基础尚未完全了解,这使得治疗干预措施(尤其是药理学干预措施)特别困难。医用大麻对神经和精神疾病的影响已经研究了很长时间。本研究旨在综述目前关于大麻素在儿科神经发育障碍中的应用的临床前和临床研究,并提请注意大麻二酚在该领域的潜在治疗作用。
大麻二酚是一种内源性大麻素系统调节剂,通过多种机制对发育中和成熟的大脑发挥作用。大麻二酚的毒性极限相对较高,目前的文献表明,它可能具有抗焦虑、抗精神病和神经保护作用。临床证据表明,早期使用大麻二酚可能是治疗神经发育障碍的一种有前途的疗法,包括智力障碍、自闭症谱系障碍、抽动症和注意/多动障碍。
本综述希望引起人们对大麻二酚在安全改善影响神经发育障碍儿童和青少年的许多常见症状方面的显著潜力的关注,特别是自闭症谱系障碍。